Діабетичний гастропарез: епідеміологія, механізми розвитку, сучасні підходи до ведення хворих
DOI:
https://doi.org/10.24026/1818-1384.2(58).2017.105532Ключові слова:
гастропарез, діабет, лікуванняАнотація
В огляді розглянуто сучасні дані відносно епідеміології, патофізіології, природного перебігу, діагностики та лікування гастропарезу, в першу чергу – діабетичного. Наявні дані стосовно високої розповсюдженості діабетичного гастропарезу та його значного впливу на наслідки та якість життя хворих вимагають оптимізації ведення хворих з цією патологією У хворих на цукровий діабет гастропарез погіршує нутритивний статус та глікемічний контроль, чинить негативні вторинні ефекти на органи, що може підвищувати смертність. Перша лінія лікування полягає в модифікації дієти, застосуванні таких медикаментів як протиблювотні засоби та прокінетики. Друга лінія лікування передбачає проведення електростимуляції шлунку або хірургічного втручання. Серед нових терапевтичних стратегій розглядають застосування нових прокінетиків без побічних кардіоваскулярних ефектів, агоністів греліна, стовбурових клітин.Посилання
Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263-283. https://doi.org/10.1111/j.1365-2982.2006.00760.x
Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy. A Joint Report of the Society of Nuclear Medicine and the American Neurogastroenterology and Motility Society. Am J Gastroenterol. 2008;103:753-763. https://doi.org/10.1111/j.1572-0241.2007.01636.x
Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251-1258. https://doi.org/10.1111/j.1365-2036.2007.03467.x
Bharucha AE, Kulkarni A, Choi KM, et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin Pharmacol Ther. 2010;87:187-190. https://doi.org/10.1038/clpt.2009.221
Bharucha AE, Camilleri M, Forstrom L, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol. 2008;70:415-420.
Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354-360. https://doi.org/10.1053/gast.2001.21166
Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2003;1:264-272. https://doi.org/10.1016/s1542-3565(03)00130-7
Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996. https://doi.org/10.1001/archinte.161.16.1989
Camilleri M, Vazquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR, Druzgala P. Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19:30-38. https://doi.org/10.1111/j.1365-2982.2006.00865.x
Camilleri M. The stomach in diabetes: from villain to ally. Clin Gastroenterol Hepatol. 2009;7:285-287. https://doi.org/10.1016/j.cgh.2008.10.031
Camilleri M, Bharucha AE, Farrugia G. Epidemiology, Mechanisms, and Management of Diabetic Gastroparesis. Clin Gastroenterol Hepatol. 2011;9:5-12. https://doi.org/10.1016/j.cgh.2010.09.022
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical Guideline: Management of Gastroparesis. Am J Gastroenterol. 2013;108:18-37. https://doi.org/10.1038/ajg.2012.373
Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol. 2010;8:676-681. https://doi.org/10.1016/j.cgh.2010.04.027
Choi KM, Gibbons SJ, Nguyen TV, et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology. 2008;135:2055-2064.e2. https://doi.org/10.1053/j.gastro.2008.09.003
Choi KM, Kashyap PC, Dutta N, et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology. 2010;138:2399-2409.e1. https://doi.org/10.1053/j.gastro.2010.02.014
Choung RS, Locke GR, Schleck C, Zinsmeister A, Talley NJ. Cumulative incidence of gastroparesis in people with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2008;103(Suppl):S309.
Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69:1853-1878. https://doi.org/10.2165/11203680-000000000-00000
Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179-1187. https://doi.org/10.1111/j.1365-2036.2009.03986.x
Farrugia G. Interstitial cells of Cajal in health and disease. Neurogastroenterol Motil. 2008;20:54-63. https://doi.org/10.1111/j.1365-2982.2008.01109.x
Forster J, Damjanov I, Lin Z, et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005;9:102-108. https://doi.org/10.1016/j.gassur.2004.10.001
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416-423. https://doi.org/10.1111/j.1572-0241.2007.01676.x
Gangula PR, Mukhopadhyay S, Ravella K, et al. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric emptying and nNOS expression in female diabetic rats. Am J Physiol. 2010;298:G692-G699. https://doi.org/10.1152/ajpgi.00450.2009
Gumaste V, Baum J. Treatment of Gastroparesis: An Update. Digestion. 2008;78:173-179. https://doi.org/10.1159/000185690
Hasler WL, Wilson L, Parkman HP, et al. Importance of abdominal pain as a symptom in gastroparesis: relation to clinical factors, disease severity, quality of life, gastric retention, and medication use. Gastroenterology. 2010;138(Supplement 1):S-461. https://doi.org/10.1016/s0016-5085(10)62131-2
Harberson J, Thomas RM, Harbison SP, Parkman HP. Gastric neuromuscular pathology in gastroparesis: analysis of full-thickness antral biopsies. Dig Dis Sci. 2010;55:359-370. https://doi.org/10.1007/s10620-009-1071-2
He CL, Soffer EE, Ferris CD, et al. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology. 2001;121:427-434. https://doi.org/10.1053/gast.2001.26264
Hyett B, Martinez FJ, Gill BM, et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology. 2009;137:445-452. https://doi.org/10.1053/j.gastro.2009.04.055
Horváth VJ, Vittal H, Lörincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology. 2006;130:759-770. https://doi.org/10.1053/j.gastro.2005.12.027
Iltz JL, Baker DE, Setter SM, Keith Campbell R. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006;28:652-665. https://doi.org/10.1016/j.clinthera.2006.05.006
Jones KL, Russo A, Berry MK, et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med. 2002;113:449-455. https://doi.org/10.1016/s0002-9343(02)01228-7
Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225-1233. https://doi.org/10.1053/j.gastro.2008.12.047
Kashyap PC, Choi KM, Dutta N, et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am J Physiol. 2010;298:G1013-G1019. https://doi.org/10.1152/ajpgi.00069.2010
Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1999;22:503-507. https://doi.org/10.2337/diacare.22.3.503
Lurken MS, Parkman HP, Abell TL, et al. Histological changes in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil. 2009;21:74.
Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22:42-49, e7-8. https://doi.org/10.1111/j.1365-2982.2009.01378.x
McCallum RW, Dusing RW, Sarosiek I, et al. Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients. Neurogastroenterol Motil. 2010;22:161–e51. https://doi.org/10.1111/j.1365-2982.2009.01389.x
Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55:675-683. https://doi.org/10.1007/s10620-009-1038-3
O'Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009;33:1693-1701. https://doi.org/10.1007/s00268-009-0096-1
Ordög T, Hayashi Y, Gibbons SJ. Cellular pathogenesis of diabetic gastroenteropathy. Minerva Gastroenterol Dietol. 2009;55:315-343.
Parkman HP, Hasler WL, Barnett JL, Eaker EY, American Motility Society Clinical GI Motility Testing Task Force. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil. 2003;15:89-102. https://doi.org/10.1046/j.1365-2982.2003.00396.x
Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592-1622. https://doi.org/10.1053/j.gastro.2004.09.055
Pasricha PJ, Pehlivanov ND, Gomez G, et al. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol. 2008;30:8-21. https://doi.org/10.1186/1471-230x-8-21
Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230-1234. https://doi.org/10.1016/s0002-9270(98)00337-2
Punkkinen J, Färkkilä M, Mätzke S, et al. Upper abdominal symptoms in patients with Type 1 diabetes: unrelated to impairment in gastric emptying caused by autonomic neuropathy. Diabet Med. 2008;25:570-577. https://doi.org/10.1111/j.1464-5491.2008.02428.x
Rao AS, Camilleri M. Review article: Metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11-19. https://doi.org/10.1111/j.1365-2036.2009.04189.x
Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036-2045. https://doi.org/10.1111/j.1572-0241.2007.01255.x
Reddymasu SC, Sarosiek I, McCallum RW. Severe gastroparesis: medical therapy or gastric electrical stimulation. Clin Gastroenterol Hepatol. 2010;8:117-124. https://doi.org/10.1016/j.cgh.2009.09.010
Talley NJ, Young L, Bytzer P, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol. 2001;96:71-76. https://doi.org/10.1111/j.1572-0241.2001.03350.x
Uppalapati SS, Ramzan Z, Fisher RS, Parkman HP. Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci. 2009; 54:2404-2409. https://doi.org/10.1007/s10620-009-0975-1
Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol. 2008;103:313-322. https://doi.org/10.1111/j.1572-0241.2007.01658.x
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
